Patients with type 2 diabetes prescribed GLP-1 receptor agonists or SGLT2 inhibitors did not have a greater risk of developing autoimmune disease than those prescribed DPP-4 inhibitors.
-like peptide 1 receptor agonists , sodium-glucose cotransporter-2 inhibitors, or dipeptidyl peptidase-4 inhibitors.The effect of GLP-1-RAs and SGLT2 inhibitors on autoimmune rheumatic disease is understudied, though previous case reports and one study have hinted at increased risk.
Researchers used administrative health data from 2014 to 2021 to identify 34,400 patients prescribed GLP-1-RAs and 83,500 patients prescribed SGLT2 inhibitors. They compared patients prescribed GLP-1-RAs or SGLT2 inhibitors with 68,400 patients prescribed DPP-4 inhibitors, which previous studies suggest do not increase ARD risk.There were no significant differences in incident ARDs between the three groups.The hazard ratio for developing ARDs with GLP-1-RAs exposure was 0.93 compared with DPP-4 inhibitors.There were no significant differences in incident ARDs between the three groups.The hazard ratio for developing ARDs with GLP-1-RAs exposure was 0.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Certain Type 2 Diabetes Drugs Lower Risk of Kidney StonesPatients with type 2 diabetes treated with SGLT2 inhibitors vs other common diabetes drugs show up to a 31% reduced risk of kidney stone development.
Read more »
Study Suggests Mind-Body Benefits of GLP-1sMed record data shows improvements in anxiety and depression in people taking the drugs for either diabetes or obesity.
Read more »
GLP-1s' Next Target: Male Infertility?Most data on GLP-1 RAs and male fertility come from animal trials or small studies investigating weight loss, but experts say there might be potential here.
Read more »
Postdoctoral Fellow in Medicinal Chemistry for Cancer Drug Discovery - Ann Arbor, Michigan job with University of MichiganJob Description Postdoctoral position is available in the laboratory of Prof. Tomasz Cierpicki, University of Michigan, Ann Arbor, to develop small molecule inhibitors for targeted therapies in cancer. We are seeking for highly motivated synthetic organic chemist or medicinal chemist to join a comprehensive drug discovery program. Dr.
Read more »
Türkiye aims to deliver 200,000 homes in quake zone by end of 2024: Erdogan'Every life we rescued from under the rubble renewed our hopes as a nation,' Turkish President Recep Tayyip Erdogan says during key handover ceremony of post-earthquake houses in Kahramanmaras province.
Read more »
GLP-1 Agonists and SGLT2 Inhibitors Do Not Increase Autoimmune RiskPatients with type 2 diabetes prescribed GLP-1 receptor agonists or SGLT2 inhibitors did not have a greater risk of developing autoimmune disease than those prescribed DPP-4 inhibitors.
Read more »